However, in patients with HER2‐positive breast cancer, for which the combination of chemotherapy and anti‐HER2 therapy is currently the standard first‐line treatment,24, 25 insufficient data are available to enable a consensus to be reached regarding the role of endocrine therapy in the subset of patients with ER‐positive tumors. This evidence concerns the gene ERBB2 and breast cancer.